Drug Candidate for Treatment of Decompensated Heart Failure
APD418 is a first-in-class calcium-independent myofilament derepressor (CMD) for decompensated heart failure (DHF). APD418 is a β3 adrenergic receptor (AdrR) selective antagonist designed to improve cardiac contractility with minimal effect on heart rate and blood pressure. Inhibition of β3 AdrR mediated myofilament repression may provide a unique cardiomyocyte-specific target to enhance cardiac contractile performance while avoiding adverse events associated with current inotrope therapies. Arena discovered and developed this investigational drug candidate internally.
About Decompensated Heart Failure
Heart failure (HF) is a clinical syndrome characterized by inadequate systemic perfusion to meet the body’s metabolic demands as a result of impaired cardiac pump function. It is one of the leading cardiovascular health problems, and its incidence, particularly in the elderly, continues to increase. Decompensated heart failure (DHF) is characterized by an increase in symptoms such as difficulty breathing (dyspnea), exertional intolerance, leg or feet swelling, and fatigue. DHF is a complex disease that often requires adjustment in medications, and is the leading cause of hospitalization for those over 65 years of age. There have been very few new medical therapies approved over the last 20 years and the mortality rate remains high.
Status
IND filing anticipated Q4 2019
| Drug Candidate |
Disease Area |
Target |
Status |
| APD418 |
Decompensated heart failure |
β3 adrenergic receptor
(AdrR) antagonist |
Preclinical |
|
| Retained Rights |
| Worldwide |
|
APD418 has not been approved by the US Food and Drug Administration or any other regulatory agency.
| Drug Candidate |
Disease Area |
Status |
| APD418 |
Decompensated heart failure
β3 adrenergic receptor
(AdrR) antagonist |
Preclinical |
|
| Retained Rights |
| Worldwide |
|